Literature DB >> 21469125

In vivo diabetogenic action of CD4+ T lymphocytes requires Fas expression and is independent of IL-1 and IL-18.

Li Wen1, Elizabeth A Green, Thomas Stratmann, Anaïs Panosa, Ramon Gomis, Elizabeth E Eynon, Richard A Flavell, Jovita A Mezquita, Conchi Mora.   

Abstract

CD4(+) T lymphocytes are required to induce spontaneous autoimmune diabetes in the NOD mouse. Since pancreatic β cells upregulate Fas expression upon exposure to pro-inflammatory cytokines, we studied whether the diabetogenic action of CD4(+) T lymphocytes depends on Fas expression on target cells. We assayed the diabetogenic capacity of NOD spleen CD4(+) T lymphocytes when adoptively transferred into a NOD mouse model combining: (i) Fas-deficiency, (ii) FasL-deficiency, and (iii) SCID mutation. We found that CD4(+) T lymphocytes require Fas expression in the recipients' target cells to induce diabetes. IL-1β has been described as a key cytokine involved in Fas upregulation on mouse β cells. We addressed whether CD4(+) T cells require IL-1β to induce diabetes. We also studied spontaneous diabetes onset in NOD/IL-1 converting enzyme-deficient mice, in NOD/IL-1β-deficient mice, and CD4(+) T-cell adoptively transferred diabetes into NOD/SCID IL-1β-deficient mice. Neither IL-1β nor IL-18 are required for either spontaneous or CD4(+) T-cell adoptively transferred diabetes. We conclude that CD4(+) T-cell-mediated β-cell damage in autoimmune diabetes depends on Fas expression, but not on IL-1β unveiling the existing redundancy regarding the cytokines involved in Fas upregulation on NOD β cells in vivo.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21469125      PMCID: PMC3787861          DOI: 10.1002/eji.201041216

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  40 in total

Review 1.  Blockade of interleukin 1 in type 1 diabetes mellitus.

Authors:  Thomas Mandrup-Poulsen; Linda Pickersgill; Marc Yves Donath
Journal:  Nat Rev Endocrinol       Date:  2010-03       Impact factor: 43.330

2.  Inhibition of autoimmune diabetes by Fas ligand: the paradox is solved.

Authors:  S Kim; K A Kim; D Y Hwang; T H Lee; N Kayagaki; H Yagita; M S Lee
Journal:  J Immunol       Date:  2000-03-15       Impact factor: 5.422

3.  IL-1alpha, IL-1beta, and IFN-gamma mark beta cells for Fas-dependent destruction by diabetogenic CD4(+) T lymphocytes.

Authors:  A Amrani; J Verdaguer; S Thiessen; S Bou; P Santamaria
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

4.  Nitric oxide production and Fas surface expression mediate two independent pathways of cytokine-induced murine beta-cell damage.

Authors:  U Zumsteg; S Frigerio; G A Holländer
Journal:  Diabetes       Date:  2000-01       Impact factor: 9.461

5.  Cytokine induction of Fas gene expression in insulin-producing cells requires the transcription factors NF-kappaB and C/EBP.

Authors:  M I Darville; D L Eizirik
Journal:  Diabetes       Date:  2001-08       Impact factor: 9.461

6.  Protection of human islets from the effects of interleukin-1beta by adenoviral gene transfer of an Ikappa B repressor.

Authors:  N Giannoukakis; W A Rudert; M Trucco; P D Robbins
Journal:  J Biol Chem       Date:  2000-11-24       Impact factor: 5.157

7.  Fas/Fas ligand interactions play an essential role in the initiation of murine autoimmune diabetes.

Authors:  Maki Nakayama; Masao Nagata; Hisafumi Yasuda; Kenji Arisawa; Reiko Kotani; Katsumi Yamada; Shahead Ali Chowdhury; Sagarika Chakrabarty; Zhen Zi Jin; Hideo Yagita; Koichi Yokono; Masato Kasuga
Journal:  Diabetes       Date:  2002-05       Impact factor: 9.461

8.  Mechanisms of accelerated immune-mediated diabetes resulting from islet beta cell expression of a Fas ligand transgene.

Authors:  Diego G Silva; Nikolai Petrovsky; Luis Socha; Robyn Slattery; Paul Gatenby; Brett Charlton
Journal:  J Immunol       Date:  2003-05-15       Impact factor: 5.422

9.  Fas and Fas ligand immunolocalization in pancreatic islets of NOD mice during spontaneous and cyclophosphamide-accelerated diabetes.

Authors:  S Redd; S Ginn; J M Ross
Journal:  Histochem J       Date:  2002 Jan-Feb

10.  Contribution of Fas to diabetes development.

Authors:  Alexei Y Savinov; Andrew Tcherepanov; E Allison Green; Richard A Flavell; Alexander V Chervonsky
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-13       Impact factor: 11.205

View more
  8 in total

Review 1.  Type 1 diabetes therapy beyond T cell targeting: monocytes, B cells, and innate lymphocytes.

Authors:  F Susan Wong; Li Wen
Journal:  Rev Diabet Stud       Date:  2012-12-28

2.  NLRP3 deficiency protects from type 1 diabetes through the regulation of chemotaxis into the pancreatic islets.

Authors:  Changyun Hu; Heyuan Ding; Yangyang Li; James A Pearson; Xiaojun Zhang; Richard A Flavell; F Susan Wong; Li Wen
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-24       Impact factor: 11.205

3.  Therapy: Immunotherapy for T1DM--targeting innate immunity.

Authors:  F Susan Wong; Li Wen
Journal:  Nat Rev Endocrinol       Date:  2013-06-04       Impact factor: 43.330

4.  Fas/Fas-Ligand Interaction As a Mechanism of Immune Homeostasis and β-Cell Cytotoxicity: Enforcement Rather Than Neutralization for Treatment of Type 1 Diabetes.

Authors:  Esma S Yolcu; Haval Shirwan; Nadir Askenasy
Journal:  Front Immunol       Date:  2017-03-27       Impact factor: 7.561

Review 5.  100 years post-insulin: immunotherapy as the next frontier in type 1 diabetes.

Authors:  James A Pearson; Eoin F McKinney; Lucy S K Walker
Journal:  Immunother Adv       Date:  2021-11-24

Review 6.  The role of the innate immune system in destruction of pancreatic beta cells in NOD mice and humans with type I diabetes.

Authors:  Ningwen Tai; F Susan Wong; Li Wen
Journal:  J Autoimmun       Date:  2016-03-24       Impact factor: 7.094

Review 7.  Inflammasomes and Type 1 Diabetes.

Authors:  James Alexander Pearson; F Susan Wong; Li Wen
Journal:  Front Immunol       Date:  2021-06-09       Impact factor: 7.561

Review 8.  The NLRP3 Inflammasome and Its Role in T1DM.

Authors:  Xiaoxiao Sun; Haipeng Pang; Jiaqi Li; Shuoming Luo; Gan Huang; Xia Li; Zhiguo Xie; Zhiguang Zhou
Journal:  Front Immunol       Date:  2020-08-27       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.